NCT03368846View on ClinicalTrials.gov

Open, Single-dose/-Period Study to Assess Mass Balance Recovery, Metabolite Profile/Identification of 14C-Varlitinib

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 23, 2017

Primary Completion Date

December 6, 2017

Study Completion Date

December 14, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

Varlitinib

\[14C\]-Varlitinib

Trial Locations (1)

Unknown

Quotient Clinical Ltd, Nottingham

Sponsors
All Listed Sponsors
lead

ASLAN Pharmaceuticals

OTHER

NCT03368846 - Open, Single-dose/-Period Study to Assess Mass Balance Recovery, Metabolite Profile/Identification of 14C-Varlitinib | Biotech Hunter | Biotech Hunter